Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

ABSTRACT: Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing. To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity. Methods: Sixty-two children (6-17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg-1 LBW). Plasma pantoprazole concentrations were measured at 10 time points over 8 h and pharmacokinetic (PK) profiles generated using non-compartmental techniques, in order to compare PK parameters of interest between children with and without obesity, while accounting for CYP2C19 genotype. Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent

SUBMITTER: Shakhnovich V 

PROVIDER: S-EPMC6309791 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature